Isturisa (osilodrostat) prior authorization for Cushing's disease
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Defines recommended prior authorization criteria, documentation, and approval durations for Isturisa (osilodrostat) for adult patients with endogenous Cushing's syndrome/Cushing's disease when surgery is not an option or not curative. Affects prescribers and payers managing pharmacy benefit coverage.
No material clinical or coverage changes in this revision.
Recommended Authorization Criteria
inv-11: Initial therapy requirements — Initial therapy eligibility for endogenous Cushing's syndrome
Initial therapy eligibility for endogenous Cushing's syndrome
inv-12: Continuation therapy requirements — Criteria for patients currently receiving Isturisa for at least 6 months
Criteria for patients currently receiving Isturisa for at least 6 months
Coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. The policy states that Isturisa has not been shown to be effective, or has limited/preliminary data or potential safety concerns, for certain conditions and that the list of Conditions Not Recommended for Approval is not exhaustive. Criteria will be updated as new published data become available.
Prior Authorization and Documentation Requirements
Prior authorization required for Isturisa
Prior authorization is recommended for pharmacy benefit coverage of Isturisa. Initial approval requires the drug be prescribed by or in consultation with a physician who specializes in the condition being treated; approvals for initial therapy are provided for the initial approval duration and reauthorization requires documented response to therapy when applicable.
- Prior authorization recommended for pharmacy benefit coverage of Isturisa.
- Initial prescriptions must be by or in consultation with an endocrinologist or specialist in Cushing's syndromes.
- Initial approvals are for the initial approval duration; reauthorization generally requires evidence of response.
No step therapy required
No step therapy sequence is specified in this policy; the document does not require trial of alternative agents prior to approval.
- Step therapy: Not specified in the policy.
Documentation the payer may request
The Company may request additional documentation to support coverage decisions; providers must make requested records and supporting information available upon request.
- Documentation that may be requested includes patient records and test results (e.g., baseline urinary free cortisol, serum potassium, serum magnesium).
- Provider credentials or documentation of consultation with a specialist may be requested.
- Additional documentation supporting medical necessity must be provided upon request.
Denial risks and required documentation
The Company may deny reimbursement if the drug or services are determined not medically necessary, investigational/experimental, outside member benefits, or if inappropriate/excessive billing or insufficient documentation is identified.
- Denial risks include lack of medical necessity, investigational/experimental use, not within member benefits, or patterns of inappropriate/excessive billing.
- Insufficient supporting documentation (e.g., missing baseline UFC or baseline labs) may lead to denial.
Therapy Duration and Coding Notes
Clinical Definitions
Drug Background
Isturisa (osilodrostat) is a cortisol synthesis inhibitor that blocks cortisol formation by inhibiting 11-beta-hydroxylase and is FDA-approved for adults with endogenous Cushing's syndrome/Cushing's disease when pituitary surgery is not an option or has not been curative. It is used both as initial therapy when surgery is not possible or curative or while awaiting surgery or the effect of radiotherapy, and for patients currently receiving therapy with demonstrated response.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.